Table 2. H. pylori -CSAs and CagA seropositivity and the risk of stomach adenocarcinoma overall, cardia site and non-cardia site.

		Stomach adenocarcinoma			Cardia adenocarcinoma			Non-cardia adenocarcinoma
Serological test results		Case	Control	OR*(95% CI)	Case	Control	OR*(95% CI)	Case	Control	OR*(95% CI)
Hp-CSAs antibodies	Negative	20	76	Ref.	12	21	Ref.	6	51	Ref.
	Positive	39	41	4.1 (1.9–8.5)	3	9	0.5 (0.1–2.8)	35	30	17.1 (4.0–72.9)
CagA antibodies	Negative	19	70	Ref.	11	19	Ref.	7	49	Ref.
	Positive	40	47	3.5 (1.7–7.1)	4	11	0.6 (0.2–2.5)	34	32	10.9 (3.2–36.9)
Hp-CSAs – CagA antibodies	Hp-CSAs and CagA antibodies negative	15	61	Ref.	10	18	Ref.	4	41	Ref.
	Hp-CSAs or CagA antibodies positive	44	56	3.3 (1.6–6.7)	5	12	0.8 (0.2–2.7)	37	40	9.7 (2.9–32.9)
	Hp-CSAs and CagA antibodies positive	35	32	5.5 (2.3–12.9)	2	8	0.3 (0.03–2.6)	32	22	48.5 (5.8–407.4)

* Odds ratios (ORs) were derived from conditional logistic regression models.